Andere Sprachen Corvus Pharmaceuticals, Inc.

Aktien

A2AFXS

US2210151005

CRVS

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 15.04.2024			% 5 Tage	% 1. Jan.
1,47 ^USD	-3,92 %		-14,04 %	-16,48 %

09.04.	Corvus Pharmaceuticals, Inc. gibt den Beginn einer placebokontrollierten klinischen Phase-1-Studie mit Soquelitinib bei atopischer Dermatitis bekannt	CI
21.03.	CORVUS PHARMACEUTICALS, INC. : Oppenheimer behält seine Kaufempfehlung bei	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Corvus Pharmaceuticals Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09.04.
Corvus Pharmaceuticals, Inc. Announces Initiation of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis	09.04.
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	20.03.
Corvus Pharmaceuticals to Start Phase 1 Study of Atopic Dermatitis Treatment in Q2	19.03.
Corvus: Q4 Earnings Snapshot	19.03.
Corvus Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results	19.03.
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	19.03.
Corvus Pharmaceuticals, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	19.03.
Corvus Pharmaceuticals to Provide Business Update and Fourth Quarter and Full Year 2023 Financial Results on March 19, 2024	13.03.
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data at the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12.02.
Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data At the Keystone Symposia on Systemic Autoimmune and Autoinflammatory Diseases	12.02.
Sector Update: Health Care Stocks Mixed in Afternoon Trading	09.02.
Sector Update: Health Care Stocks Mixed Pre-Bell Friday	09.02.
Corvus Pharmaceuticals Says Soquelitinib Received FDA Orphan Drug Designation	09.02.
Corvus Pharmaceuticals Shares Rise on Orphan Drug Designation	08.02.
Corvus Pharmaceuticals Announces Orphan Drug Designation Granted to Soquelitinib for the Treatment of T Cell Lymphoma	08.02.
Corvus Pharmaceuticals Appoints Jeffrey Arcara as Chief Business Officer	06.02.
Corvus Pharmaceuticals, Inc. Appoints Jeffrey Arcara as Chief Business Officer	06.02.
Corvus Pharmaceuticals Announces the Passing of Board Member Edith P. Mitchell	23.01.
Corvus Pharmaceuticals Announces Demise of Edith P. Mitchell, Member of the Board of Directors	23.01.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Corvus Pharmaceuticals, Inc.

Aktien

A2AFXS

US2210151005

CRVS

Andere Sprachen

Filter